1. Home
  2. PED vs GANX Comparison

PED vs GANX Comparison

Compare PED & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PED
  • GANX
  • Stock Information
  • Founded
  • PED N/A
  • GANX 2017
  • Country
  • PED United States
  • GANX United States
  • Employees
  • PED N/A
  • GANX N/A
  • Industry
  • PED Oil & Gas Production
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PED Energy
  • GANX Health Care
  • Exchange
  • PED Nasdaq
  • GANX Nasdaq
  • Market Cap
  • PED 48.8M
  • GANX 53.8M
  • IPO Year
  • PED N/A
  • GANX 2021
  • Fundamental
  • Price
  • PED $0.72
  • GANX $1.77
  • Analyst Decision
  • PED Strong Buy
  • GANX Strong Buy
  • Analyst Count
  • PED 2
  • GANX 5
  • Target Price
  • PED $1.63
  • GANX $8.20
  • AVG Volume (30 Days)
  • PED 486.8K
  • GANX 247.1K
  • Earning Date
  • PED 08-13-2025
  • GANX 08-07-2025
  • Dividend Yield
  • PED N/A
  • GANX N/A
  • EPS Growth
  • PED 2248.88
  • GANX N/A
  • EPS
  • PED 0.19
  • GANX N/A
  • Revenue
  • PED $40,173,000.00
  • GANX N/A
  • Revenue This Year
  • PED N/A
  • GANX N/A
  • Revenue Next Year
  • PED $5.99
  • GANX N/A
  • P/E Ratio
  • PED $3.78
  • GANX N/A
  • Revenue Growth
  • PED 30.70
  • GANX N/A
  • 52 Week Low
  • PED $0.47
  • GANX $0.89
  • 52 Week High
  • PED $1.10
  • GANX $3.19
  • Technical
  • Relative Strength Index (RSI)
  • PED 59.82
  • GANX 44.69
  • Support Level
  • PED $0.66
  • GANX $1.85
  • Resistance Level
  • PED $0.78
  • GANX $1.81
  • Average True Range (ATR)
  • PED 0.04
  • GANX 0.15
  • MACD
  • PED 0.01
  • GANX -0.01
  • Stochastic Oscillator
  • PED 52.32
  • GANX 32.61

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: